Determinants of Propranolol's Selective Effect on Loss Aversion
Related Experiment Video
Updated: Apr 10, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker
Published on: December 18, 2014
Peter Sokol-Hessner1, Sandra F Lackovic2, Russell H Tobe3
1Department of Psychology, New York University Center for Neural Science, New York University.
Abstract:
Research on emotion and decision making has suggested that arousal mediates risky decisions, but several distinct and often confounded processes drive such choices. We used econometric modeling to separate and quantify the unique contributions of loss aversion, risk attitudes, and choice consistency to risky decision making. We administered the beta-blocker propranolol in a double-blind, placebo-controlled within-subjects study, targeting the neurohormonal basis of physiological arousal. Matching our intervention's pharmacological specificity with a quantitative model delineating decision-making components allowed us to identify the causal relationships between arousal and decision making that do and do not exist. Propranolol selectively reduced loss aversion in a baseline- and dose-dependent manner (i.e., as a function of initial loss aversion and body mass index), and did not affect risk attitudes or choice consistency. These findings provide evidence for a specific, modulatory, and causal relationship between precise components of emotion and risky decision making.
More Related Videos
13:20Online Repetitive Transcranial Magnetic Stimulation of Dorsomedial and Dorsolateral Prefrontal Cortex in Cognition Decision Making, and Cognitive Dissonance
Published on: December 5, 2025
07:05Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
Published on: September 10, 2018
Related Concept Videos
Antihypertensive Drugs: Types of β-Blockers
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Dose-Response Relationship: Selectivity and Specificity
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers